Novosteo Inc., a Purdue University-affiliated startup known for its novel injectable drug to heal broken bones, has added a new scientist to its team.
 
Novosteo was co-founded by father-son team Philip S. Low, the presidential scholar for Drug Discovery and the Ralph C. Corley distinguished professor of chemistry, and Stewart A. Low, the company’s chief scientific officer and visiting scholar in Purdue’s Department of Chemistry.
 
The new addition to the Novosteo team is Jeffery Nielsen, a Purdue alumnus, who serves as director of research and development. Nielsen was hit by a moving truck as a child. The impact crushed his skull and broke dozens of bones.
 
“Recovery from bone fractures was tough as a child, but we know it is significantly more difficult for older adults,” Nielsen said. “I am driven to use my personal and professional experiences to help improve lives.”
 
Nielsen previously worked with targeted bone therapies, technology startups and organ growth procedures.
 
Novosteo is already looking at the future use of injectable-targeted drugs for other applications, including dental implants, head and facial fractures, and hip and knee replacements. Novosteo also has a pipeline of drugs for treating an array of musculoskeletal maladies.